Prevention of type 2 Diabetes Mellitus: Potential of pharmacological agents

详细信息    查看全文

• 作者：Susan L. Samson ; MD PhD FRCPC FACE^a ; ^{ssamson@bcm.edu" class="auth_mail" title="E-mail the corresponding author} (Associate Professor) ; Alan J. Garber ; MD PhD FACE^b ; ^c ; ^d ; ¹ (Professor)
• 关键词：type 2 diabetes ; weight loss ; obesity ; impaired glucose tolerance ; impaired fasting glucose ; diabetes prevention
• 刊名：Best Practice Research Clinical Endocrinology Metabolism
• 出版年：2016
• 出版时间：June 2016
• 年：2016
• 卷：30
• 期：3
• 页码：357-371
• 全文大小：689 K

文摘

People with impaired glucose tolerance or impaired fasting glucose, or “pre-diabetes”, are at high risk for progression to type 2 diabetes, as are those with metabolic syndrome or a history of gestational diabetes. Both glucose-lowering and anti-obesity pharmacotherapies have been studied to determine if the onset of type 2 diabetes can be delayed or prevented. Here we review the available data in the field. The most common theme is the reduction in insulin resistance, such as with weight loss, decreasing demands on the beta cell to improve insulin secretion and prolong its function. Overall, therapies which decrease diabetes incidence in high-risk populations delay the onset of diabetes but do not correct the underlying beta cell defect.